Endocrine Abstracts

Background: Antithyroid drugs (ATDs) are preferred as a first-line treatment for Graves’ disease (GD). However, around 50–60% of patients relapse following treatment withdrawal. Radioactive iodine (RAI) or thyroidectomy is recommended for these patients, however, repeat ATD therapy is a further option, dependent upon patient choice. The long-term efficacy of ATD in relapsed GD has not been robustly established.Methods: We conducted a retrospect...

Background: Current therapeutic options for Graves’ disease (GD) include antithyroid drugs (ATD), radioactive iodine (RAI) or thyroidectomy. ATD treatment is widely used but the relatively high recurrence rate (~50%) after ATD discontinuation is a major concern. Identification of risk factors predicting relapse in GD patients after stopping ATD is decisive to guide initial treatment choices.Methods: We conducted a retrospective study to determine th...